Boncz I 1 , Sebestyén A 1 , Döbrõssy L 2 , Budai A 2 , Kovács A 2 , Ember I 3 1 National Health Insurance Fund Administration, Budapest, Hungary, 2 National Public Health and Medical Officers Service (ÁNTSZ), Budapest, Hungary, 3 University of Pécs, Pécs, Hungary OBJECTIVES: Nationwide organized breast cancer screening programme was launched 2002 in Hungary for women between the age of 45-65 with a 2 years screening interval. The aim of the study is to analyse the within country inequalities of mammography coverage of the organized programme. METHODS: Data derive from the database of the National Health Insurance Fund Administration (OEP) containing routinely collected financial data. The study includes all the women aged 45-64 having either screening or diagnostic mammography before (2000) (2001) and after (2002-2003 and 2004-2005) the introduction of organized screening. The regional inequalities are calculated for 19 counties and Budapest as the capital (altogether 20 items). Coverage is defined as the proportion of women resident who have had a mammogram at least once in the previous 2 years. RESULTS: National mammography coverage was 26. 7%, 54,6% and 51,6% in 2000-2001, 2002-2003 and 2004-2005 respectively. We found the highest coverage in 2000-2001 in counties having earlier pilot screening programme: county Tolna (59.2%), county Jász-Nagykun-Szolnok (45.1%), county Zala (39.5%). After the introduction of nationwide breast screening programme in 2002-2003 we found the highest coverage in the following counties: county Szabolcs-Szatmár-Bereg 70.8%, county Borsod-Abaúj-Zemplén 64.4%, county Veszprém 63.9%. In 2004-2005, the following counties received the highest coverage: county Gyõr-Moson-Sopron (60.8%), county Szabolcs-Szatmár-Bereg 58.1% and county Vas 56.2%. The ratio of coverage between the counties with the highest and lowest coverage was 3.5 (2000-2001), 2.6 (2002-2003) and 1.4 (2004-2005) . CONCLUSION: We found significant within country differences in mammography cover-age, however the gap between counties with lowest and highest coverage became smaller after the introduction of organized screening programme.
PCN39 GAP BETWEEN INPATIENT TREATMENT COST OF AND MORTALITY DUE TO BREAST CANCER IN HUNGARY
Boncz I 1 , Sebestyén A 1 , Döbrõssy L 2 , Péntek M 3 , Gulácsi L 4 1 National Health Insurance Fund Administration, Budapest, Hungary, 2 National Public Health and Medical Officers Service (ÁNTSZ), Budapest, Hungary, 3 Flor Ferenc County Hospital, Kistarcsa, Hungary, 4 Corvinus University of Budapest, Budapest, Hungary OBJECTIVES: The aim of this study is to analyze and compare the distribution of inpatient care treatment cost of and mortality due to breast cancer according to age-groups. METHODS: Data derive from the database of the National Health Insurance Fund Administration (OEP) containing routinely collected financial data. The study includes all the women who received outpatient and/or inpatient care treatment in 2001 financed from public resources of OEP. Number of deaths due to breast cancer is from the Central Statistical Office database. We compared the annual out-and inpatient care treatment cost and the annual number of deaths according to the following age groups: 0-24, 25-44, 45-64, 65-74, 75+ . RESULTS: The cost distribution of out-and inpatient care treatment cost of breast cancer was the following (outp./inp.): 0-24 years: 0.1%/0.2%; 25-44 years: 12.4%/11.7%; 45-64 years: 59.2%/59.1%; 65-74 years: 20.9%/20.2%; 75 and over: 7.4%/8.7%. The distribution of deaths due to breast cancer was the following: 0-24 years: 0.0%; 25-44 years: 5.0%; 45-64 years: 37.0%; 65-74 years: 22.8%; 75 and over: 35.2%. We found that in the age-group 65-74 there is a balance between the cost distribution (20.9% and 20.2%) and the deaths (22.8%). Women in younger age groups received more treatment cost than its mortality would predict, while in older age groups (75+)-responsible 35.2% of deaths-received only 7.4% and 8.7% of out-and inpatient treatment cost respectively. CONCLUSION: There is a shift between the distribution of treatment cost of and deaths due to breast cancer in favor of younger age-groups.
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PATTERNS OF TREATMENT OF NON SMALL CELL LUNG CANCER (NSCLC) IN COMMUNITY PRACTICE
Kinchen K 1 , Marciniak M 1 , Obenchain R 1 , Kwan P 2 , Koeller J 3 1 Eli Lilly and Company, Indianapolis, IN, USA, 2 University of Texas, Austin, TX, USA, 3 University of Texas, San Antonio, TX, USA OBJECTIVES: Evidence guiding NSCLC treatment has been derived largely from controlled trials at academic centers. Much less attention has focused on understanding NSCLC treatment by community-based oncologists. We undertook this study to better understand NSCLC treatment patterns and outcomes in community-based practices. METHODS: Ten large communitybased oncology practices in the U.S. were identified. Investigators conducted chart reviews on 417 NSCLC patients treated with chemotherapy between 2001 and 2003 who were deceased at the time of the review. RESULTS: Of the 417 patients (54% male, median age 68 years, mean performance status 1.2) almost 20% had a history of radiation therapy, and 9.6% had a history of surgery. Mean survival was 10.5 months for stage IIIB patients (n = 114) and 7.9 months for stage IV patients (n = 303). In their first line of chemotherapy, 55% of patients received both carboplatin and paclitaxel (18% in combination with radiation therapy). Another 11% received carboplatin with either gemcitabine (6%) or doctaxel (5%). In contrast, monotherapy was more common in second line therapy (docetaxel 22%, gemc-itabine 14%, vinorelbine 11% or gefitinib 9%). Approximately one-quarter of patients were treated in third line and approximately 10% received fourth line treatment. The vast majority of third and fourth line treatments involved single agents. Toxicities associated with drug therapy were consistent with those that have been previously reported elsewhere. CONCLUSION: In the first line of therapy, patients received care largely reflecting the existing NSCLC evidence base from controlled trial data available during the 2001-2003 period. Treatment patterns and outcomes of patients in community-based practices represent a potential rich source of data to complement controlled trial data. To improve the availability of real-world practice data, further work is necessary to overcome limitations of claims-based oncology data, to enhance the development of analyzable electronic health records, and to establish treatment registries. 
PCN41 DRUG COST CONSIDERATIONS FOR ERYTHROPOIETIC STIMULATING THERAPIES (ESTS) AGENTS IN PATIENTS INITIATED AT FDA-APPROVED DOSING: RESULTS FROM PRACTICE PATTERNS IN A PROSPECTIVE OBSERVATIONAL STUDY
